Long-term effects of aprepitant on tacrolimus pharmacokinetics in allogeneic hematopoietic stem cell transplantation
Abstract Background Aprepitant (APR), including intravenous fosaprepitant, is widely used as an antiemetic for highly emetogenic chemotherapy. APR is a moderate inhibitor and inducer of CYP3A4 and may alter the pharmacokinetics of concomitant drugs over an extended period. Tacrolimus (TAC), a key immunosuppressant after allogeneic hematopoietic stem cell transplantation (allo-HSCT), is primarily metabolized by CYP3A4. The long-term effects of APR on TAC pharmacokinetics remain unclear. Methods This retrospective observational study included patients receiving TAC for at least 28 days after allo-HSCT between January 2006 and April 2017. Patients were classified into APR-treated (APR(+)) and non-APR-treated (APR(-)) groups. During the 28-day observation period, patients switched from intravenous to oral TAC were censored at conversion to exclude the influence of bioavailability. TAC was administered by continuous intravenous infusion at 0.03 mg/kg/day starting on day − 1 and adjusted by therapeutic drug monitoring to maintain a target level of 15 ng/mL. APR was initiated between day − 8 and day 1 and was administered for up to 5 days, orally or intravenously. The concentration/dose (C/D) ratio was used as a surrogate marker of TAC clearance. Results A total of 64 patients were assessed for eligibility. Of these, 16 who received voriconazole or itraconazole were excluded, leaving 48 patients (28 APR(+), 20 APR(-)). Baseline characteristics and use of moderate CYP3A4 inhibitors did not differ between groups. From days 0–4, TAC C/D ratios were similar. In APR(+), C/D ratio decreased from day 5 to day 10, remained low for approximately 3 weeks, and returned to day 5 levels by day 28. C/D values on day 10 ± 1 and day 20 ± 1 were significantly lower than APR(-) ( P < 0.01). TAC doses in APR(+) increased from around day 5, reaching approximately 30% above day 4 ± 1 during days 10–25, then decreased. Conclusions Co-administration of TAC and APR increases TAC clearance from day 5, likely due to CYP3A4 induction, and the effect persists for approximately 3 weeks. The prolonged induction may relate to concomitant fluconazole use or longer half-life of TAC. Gradual TAC dose escalation of approximately 30% from day 5, with frequent monitoring for 2–3 weeks, may help maintain adequate exposure while minimizing GVHD and adverse effects.
Authors
- Akira Honda (ORCID: https://orcid.org/0000-0001-8462-6024)
- Tappei Takada (ORCID: https://orcid.org/0000-0002-3868-9320)
- Yoshiyuki Ohno (ORCID: https://orcid.org/0009-0005-4727-8792)
- Toyohito Oriyama (ORCID: https://orcid.org/0000-0002-0142-8709)
- Mineo Kurokawa (ORCID: https://orcid.org/0000-0002-4034-2422)
- Kaoru Hitachi-Yuzawa
- Takehito Yamamoto
Institutions
- University of Tokyo Hospital (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1186/s40780-026-00639-2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00